Colorectal News and Research

RSS

Angiogenesis gene polymorphisms predict tumor recurrence in stage II and III colon cancer

Researchers at the University of Southern California (USC) have identified specific molecular markers that may help to predict tumor recurrence in stage II and III colon cancer patients.

8 Jun 2007

Folic acid does not decrease the risk of benign colorectal tumors

New research indicates that folic acid supplementation does not decrease the risk of benign colorectal tumors, but may possibly increase the risk for some types of colorectal tumors, according to a study in the June 6 issue of JAMA .

8 Jun 2007

More New Yorkers getting colonoscopies

More New Yorkers are getting life-saving colonoscopies than ever before, the Health Department announced, and people of all races and incomes are benefiting.

8 Jun 2007

Folic acid does not prevent colorectal cancer

Despite the fact that some previous studies have suggested that folate supplementation may help to prevent colorectal cancer, a new study says that is not the case and it may in fact increase the risk for some types of colorectal tumors.

6 Jun 2007

Researchers find stem cells in colorectal tumors

Researchers at the Stanford University School of Medicine have identified the cancer stem cells that propagate tumors in colon and rectal cancer, a discovery that could lead to improved treatment of this deadly cancer.

5 Jun 2007

Physiological differences between men and women impact colorectal cancer progression

Physiological differences between men and women may contribute to differential tumor development and progression in colon cancer patients, a study led by researchers at the University of Southern California (USC) suggests.

5 Jun 2007

When to change the course of treatment

Counting circulating tumor cells before and after the start of treatment for patients with metastatic colorectal cancer could help doctors determine when or if a change in treatment should be made.

5 Jun 2007

Regular aspirin intake only reduces incidence of colorectal tumors that overexpress COX-2

Aspirin therapy's ability to reduce the risk of colorectal cancer, an association seen in a large number of studies, appears to depend on the drug's inhibition of the COX-2 enzyme, the action that also underlies aspirin's usefulness for treating pain and inflammation.

24 May 2007

Guidelines on skin reactions to Epidermal Growth Factor Receptor Inhibitors (EGFRIs)

Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach , usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."

24 May 2007

Impact of lifestyle on GI health

According to new research presented at Digestive Disease Week 2007 (DDW), lifestyle factors like choosing your diet regimen or ordering an appetizer for dinner may have a significant impact on the gastrointestinal (GI) system, affecting your risk for certain diseases, weight and general GI-related activity.

22 May 2007

Study breaks link between lycopene and prostate cancer prevention

Tomatoes might be nutritious and tasty, but don't count on them to prevent prostate cancer.

18 May 2007

Britain second rate when it comes to treating cancer sufferers

When it comes to accessing the best drugs for cancer Britain is a second rate country to be sick in.

14 May 2007

Daily Aspirin reduces colon cancer risk by 74 percent

Researchers in Britain say an aspirin a day taken over a 10 year period can reduce the risk of colon cancer by as much as 74 percent.

14 May 2007

Patients around the world face stark inequalities in access to cancer treatment

The report's authors urge decision makers in every country to take action and ensure that everyone has equal access to new cancer drugs when they are needed, wherever they live.

10 May 2007

Study looks at interest level of healthy, young adults in receiving genetic testing for common conditions

The National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), parts of the National Institutes of Health (NIH), have teamed with Group Health Cooperative in Seattle and Henry Ford Health System in Detroit to launch a study to investigate the interest level of healthy, young adults in receiving genetic testing for eight common conditions.

8 May 2007

Magnesium loss In patients given monoclonal antibodies

97% of patients with cancer treated with monoclonal antibodies—cetuximab, matuzumab, or panitumumab—that target the epidermal growth factor receptor (EGFR) have some degree of magnesium loss (hypomagnesaemia), according to a study published in the May issue of The Lancet Oncology.

2 May 2007